WAVE Life Sciences Ltd.
WVE
$6.79
-$0.28-3.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 316.85% | -79.41% | 199.11% | -55.82% | -26.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 316.85% | -79.41% | 199.11% | -55.82% | -26.82% |
| Cost of Revenue | 16.78% | 18.30% | 11.35% | 7.62% | 21.45% |
| Gross Profit | 70.76% | -190.96% | 21.70% | -67.96% | -50.40% |
| SG&A Expenses | 20.41% | 29.51% | 20.24% | 25.83% | 35.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.91% | 21.27% | 13.73% | 12.38% | 25.50% |
| Operating Income | 37.16% | -345.86% | 11.83% | -50.75% | -44.54% |
| Income Before Tax | 44.35% | -281.79% | 12.83% | -53.29% | -48.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.35% | -281.79% | 12.83% | -53.29% | -48.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.35% | -281.79% | 12.83% | -53.29% | -48.55% |
| EBIT | 37.16% | -345.86% | 11.83% | -50.75% | -44.54% |
| EBITDA | 37.75% | -332.99% | 11.86% | -52.64% | -46.42% |
| EPS Basic | 54.82% | -263.00% | 31.12% | -21.09% | -18.15% |
| Normalized Basic EPS | 54.77% | -262.99% | 31.10% | -21.08% | -18.09% |
| EPS Diluted | 54.82% | -273.85% | 31.12% | -21.09% | -18.15% |
| Normalized Diluted EPS | 54.77% | -273.89% | 31.10% | -21.08% | -18.09% |
| Average Basic Shares Outstanding | 23.13% | 11.56% | 26.53% | 26.60% | 25.76% |
| Average Diluted Shares Outstanding | 23.13% | 4.56% | 26.53% | 26.60% | 25.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |